Cover Image

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review

Christos Chouaïd,1 Perinne Crequit,2 Isabelle Borget,3 Alain Vergnenegre4 1Service de Pneumologie et de Pathologie Professionnelle, Centre Hospitalier Intercommunal Créteil et Université de Paris Est Créteil, Paris, France; 2Service de Pneumologie, Hôpital Tenon, Assistance Publique-Hôpitaux de Pari...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chouaïd C (Author), Crequit P (Author), Borget I (Author), Vergnenegre A (Author)
Format:	Book
Published:	Dove Medical Press, 2014-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
by: Taipale K, et al.
Published: (2017)

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents
by: Vergnenègre A, et al.
Published: (2013)

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
by: Vergnenègre A, et al.
Published: (2012)

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
by: Guiyuan Xiang, et al.
Published: (2021)

First line Immunotherapy for Non-Small Cell Lung Cancer
by: Nicola J. Nasser, et al.
Published: (2020)

Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients
by: Meiyu Fang, et al.
Published: (2012)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
by: Tingting Lu, et al.
Published: (2023)

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
by: Xuezhi Hao, et al.
Published: (2021)

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
by: Serena Ricciardi, et al.
Published: (2009)

OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER
by: Deyan N. Davidov
Published: (2013)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
by: Yingcheng Wang, et al.
Published: (2021)

THROMBOCYTOSIS AS PROGNOSTIC FACTOR FOR SURVIVAL IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER TREATED WITH FIRST- LINE CHEMOTHERAPY.
by: Deyan Davidov
Published: (2014)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
by: Jing Wang, et al.
Published: (2023)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
by: Enriqueta Felip, et al.
Published: (2008)

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer
by: Qian-Yu Yang, et al.
Published: (2022)

Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial
by: Qin Wang, et al.
Published: (2018)

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
by: Isla D, et al.
Published: (2016)

Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer
by: Wang Y, et al.
Published: (2022)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
by: Yu Lu, et al.
Published: (2023)

Short‐Term Efficacy of Different First‐Line Chemotherapy Regimens for Advanced Non‐Small Cell Lung Cancer: A Network Meta‐Analysis
by: Bei‐Bei Zhang, et al.
Published: (2020)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023)

Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
by: Yimeng Guo, et al.
Published: (2023)

Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
by: Kehai Lin, et al.
Published: (2022)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022)

Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell
by: Jonathan González García, et al.
Published: (2017)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
by: Zhangfeng Huang, et al.
Published: (2020)

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis
by: Wei Chen, et al.
Published: (2023)

Clinical development of nintedanib for advanced non-small-cell lung cancer
by: Takeda M, et al.
Published: (2015)

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
by: Qiao Liu, et al.
Published: (2021)

Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
by: Hongxin Li, et al.
Published: (2024)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China
by: Liu Qiao, et al.
Published: (2021)

The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Ze Peng, et al.
Published: (2021)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
by: Walleser S, et al.
Published: (2012)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
by: Wenjie Liu, et al.
Published: (2024)

Comparative efficacy of six programmed cell death Protein-1 inhibitors as first-line treatment for advanced non-small cell lung cancer: a multicenter retrospective cohort study
by: Siyuan Chen, et al.
Published: (2024)

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
by: Zhiwei Zheng, et al.
Published: (2022)

Initial Systemic Treatment of Advanced Non-small Cell Lung Cancer
by: Muhammad Kamran Siddique, et al.
Published: (2019)

Cost analysis of adverse events associated with non-small cell lung cancer management in France
by: Chouaid C, et al.
Published: (2017)

"Highly Exposed Chinese Herbal Medicine" Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
by: Mingqi Wang, et al.
Published: (2021)